Trial Profile
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Prednisone
- Indications Giant cell arteritis
- Focus Therapeutic Use
- Acronyms ULTRA
- 13 Oct 2022 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 13 Oct 2022 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 16 Sep 2020 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.